Merck & Co., Inc. (MRK)

NYQ – Real Time Price. Currency in USD

112.64

+0.25 (0.22%)

Market open: May 13, 2026, 9:37 AM EDT

12.05.2026

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across over 25 types of cancer from the company's comprehensive oncology portfolio and pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-June 2). The data reinforce the long-term impact of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, and Merck's rapidly advancing pipelin.

12.05.2026

The Zacks Analyst Blog UnitedHealth, Merck & Co., Qualcomm, EVI and Optex

UNH, MRK and QCOM drew focus as analysts highlighted growth drivers, pipeline strength and expanding AI and automotive opportunities.

11.05.2026

Merck Stock Down 7% in a Month: Should Investors Hold or Exit?

Merck falls 7% despite an earnings beat as a pipeline setback and Gardasil weakness act as dampeners. However, Keytruda and new launches support growth.

08.05.2026

2 Dividend Stocks to Double Up On Right Now

Amgen is handling a recent patent cliff pretty well. Merck is well prepared for its own upcoming patent cliff.

07.05.2026

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the publication of work describing the large-scale synthesis of enlicitide decanoate, the company's investigational oral PCSK9 inhibitor, using a tailored suite of enzymes in the latest issue of the peer reviewed journal Science. “Macrocyclic peptides have the potential to unlock new opportunities to develop oral treatment options for challenging therapeutic targets and broaden p.

06.05.2026

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

06.05.2026

Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

SAN FRANCISCO & RAHWAY, N.J.--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world's #1 AI CRM, and Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), today announced that Merck Animal Health has selected Agentforce Life Sciences for Customer Engagement to create a unified, 360-degree view and support experience for veterinarians, pet owners, and production animal farmers across all channels. Leveraging Agentfo.

Videos

04.02.2026

Positive

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

30.01.2026

Positive

5 Stocks That Could Outperform Even in a Pullback

26.01.2026

Negative

Overlooked Stock: RVMD Sells After MRK Turns Away

09.01.2026

Neutral

Trade Tracker: Kevin Simpson buys FedEx, SLB and sells a covered call on Merck

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
MRK	Scotiabank	Sector Outperform	undefined >> $105	November 13th 2025
MRK	Citigroup	Neutral	undefined >> $95	October 13th 2025
MRK	Berenberg	Hold	undefined >> $90	September 17th 2025
MRK	Citigroup	Neutral	undefined >> $84	May 14th 2025
MRK	Cantor Fitzgerald	Neutral	undefined >> $85	April 22nd 2025
MRK	Deutsche Bank	Hold	$128 >> $105	February 18th 2025
MRK	TD Cowen	Hold	$121 >> $100	February 10th 2025
MRK	Truist	Hold	undefined >> $110	January 8th 2025

Press releases

12.05.2026

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

07.05.2026

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

06.05.2026

Merck Animal Health Selects Salesforce's Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees

05.05.2026

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). “The Terns acquisition reflects Merck's continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients,” said Robert M. Davis, chairman and chief executive officer, Merck. “We believe TERN‑701 has the potential to be.

Merck & Co., Inc. (MRK)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Merck & Co., Inc. (MRK)

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026

The Zacks Analyst Blog UnitedHealth, Merck & Co., Qualcomm, EVI and Optex

Merck Stock Down 7% in a Month: Should Investors Hold or Exit?

2 Dividend Stocks to Double Up On Right Now

Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash